You are here: Industry Insights > PCSK9

News List

Novo Nordisk BASEA office certified Best Place to Work for 2021 prnasia
December 24, 2021
Today, Akeso, Inc. (09926.HK) announces that Ebronucimab (PCSK9 monoclonal antibody, research and development code: AK102), jointly developed by the Company and Dawnrays Biotechnology Capital (Asia) Ltd.
AstraZeneca Initiates Study of Antisense Med Targeting PCSK9 to Lower LDL-Cholesterol americanpharmaceuticalreview
December 17, 2020
Ionis Pharmaceuticals announced that biopharmaceutical company AstraZeneca has initiated a Phase 2b clinical trial of ION449 (AZD8233), an investigational antisense medicine designed to reduce blood cholesterol levels in patients with dyslipidemia by ...
U.S. District Court Invalidates Amgen Patent Claims Targeting PCSK9 americanpharmaceuticalreview
September 03, 2019
Regeneron Pharmaceuticals and Sanofi announced the U.S. District Court for the District of Delaware ruled in their favor and found as a matter of law that Amgen's asserted patent claims for antibodies targeting PCSK9 ...
Sanofi, Regeneron score win against Amgen patents on PCSK9 med Repatha fiercepharma
September 02, 2019
Sanofi and Regeneron have been battling with PCSK9 rival Amgen over patents on their cholesterol drugs for years, with Amgen at one point blocking sales of the partners’ Praluent. Now, Sanofi and Regeneron have persuaded a judge that certain claims of two
Higher Cost of New Cholesterol Drugs Putting Patients at Risk: Study drugs
July 24, 2019
Heart attacks, strokes and other heart problems are more likely in high-risk patients denied access to cutting-edge cholesterol-busting drugs called PCSK9 inhibitors...
PCSK9 price-cut matchup is on, as Regeneron and Sanofi slash Praluent list tag 60% fiercepharma
February 24, 2019
It’s not often that a tit-for-tat pricing battle goes public in biopharma—and that sort of fight is perhaps even more rare for prerebate list prices.